AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing market with new free offering.| CNBC
In the end, Saudi Arabia may have only one option: Launch a supply war by flooding the market with oil.| CNBC
Citi isn't alone in liking this biotech firm. According to FactSet, analysts covering the stock give it an average price target upside of 385%.| CNBC
Some people may actually gain back more weight than they initially lost after stopping obesity drugs Ozempic and Wegovy.| CNBC
The burgeoning weight-loss drug industry could be worth as much as $200 billion within the next decade, according to Barclays bank.| CNBC